Kazakhstan begins vaccinating 3 thousand volunteers with the domestic QazCovid-in vaccine. To date, the first and the second phases of clinical trials of the vaccine have been conducted at the Biological Safety Research Institute in Zhambyl Region. According to scientists, preliminary results of the research demonstrate high safety, immunogenicity, and efficiency of the vaccine at the level of 96%. According to the press service of the head of the Cabinet of Ministers, the first volunteers were vaccinated in clinics in Almaty and Taraz. For the third phase, 10 thousand doses of vaccine will be produced.
